Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England
Adrian Kilcoyne, Edward Jordan, View ORCID ProfileKimberly Thomas, Alicia N. Pepper, Allen Zhou, Dale Chappell, Miyuru Amarapala, Rachel-Karson Thériault, Melissa Thompson
doi: https://doi.org/10.1101/2022.02.11.22270859
